Morgan Stanley
TSBX

Morgan Stanley’s Turnstone Biologics TSBX Stock Holding History

Morgan Stanley’s Portfolio TSBX Stock Details TSBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4,701
Closed -$2.34K – 8214
2024
Q4 		$2.34K Sell
4,701
-1,300
-22% -$642 ﹤0.01% 7172
2024
Q3 		$3.34K Sell
6,001
-12,758
-68% -$19.6K ﹤0.01% 7017
2024
Q2 		$49.1K Sell
18,759
-4,835
-20% -$13.8K ﹤0.01% 6178
2024
Q1 		$61.8K Sell
23,594
-7,794
-25% -$22.3K ﹤0.01% 6137
2023
Q4 		$79.9K Buy
31,388
+28,491
+983% +$74.4K ﹤0.01% 6233
2023
Q3 		$11.4K Buy
+2,897
New +$25.8K ﹤0.01% 6688

Other funds holding TSBX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
7IH
72 Investment Holdings Stamford, Connecticut $49.6M AUM 684.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley's TSBX Position: Q1 2025 in Review

Morgan Stanley sold out of Turnstone Biologics (TSBX) in Q1 2025, closing a stake of 4,701 shares — an estimated $2.34K sold.

Morgan Stanley first reported a position in TSBX in Q3 2023 and held it in 6 quarters. The position peaked at $79.9K in Q4 2023. 23 funds tracked by Wall St. Rank hold TSBX as of Q1 2025.

  • Morgan Stanley reported no remaining Turnstone Biologics position as of Q1 2025 after selling out during the quarter.
  • Morgan Stanley sold 4,701 Turnstone Biologics shares in Q1 2025, an estimated $2.34K.
  • Morgan Stanley first reported a position in Turnstone Biologics in Q3 2023 and held it in 6 quarters.
  • Morgan Stanley's Turnstone Biologics position peaked at $79.9K in Q4 2023.
  • 23 funds tracked by Wall St. Rank held Turnstone Biologics as of Q1 2025.

Based on Morgan Stanley's 13F filing for Q1 2025, filed 15 May 2025.